NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11,084 mln
Float135 mln
Earnings Date08/12/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
28.20
Transformational upside
Relative Strength
85
/ 100
Strongly outperforming
Debt / Equity
0.04
Debt-free
ROE
-301
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Summit Therapeutics is a biopharmaceutical company founded in 2003 and based in Miami, Florida, focused on developing medicines that work better for patients, doctors, and families. Its main drug candidate, ivonescimab, is a next-generation cancer treatment being tested in late-stage clinical trials for lung and colorectal cancers. The company sells its products across North America, Europe, Japan, Latin America, the Middle East, and Africa.
